Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 3/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13940831 | 1.00 | MMP13 (0.46) | MMP13CYP3A4MMP7KCNH2MMP14 | |
| SCHEMBL13941032 | 0.91 | CYP3A4 (0.56) | MMP13CYP3A4MMP7GPR119CTSS | |
| SCHEMBL3943555 | 0.88 | MMP13 (0.48) | MMP13CYP3A4MMP7KCNH2MMP14 | |
| SCHEMBL3933433 | 0.88 | MMP13 (0.45) | MMP13CYP3A4MMP7KCNH2MMP14 | |
| SCHEMBL8304525 | 0.88 | CYP3A4 (0.46) | MMP13CYP3A4MMP7MMP14HSD11B1 | |
| SCHEMBL3936734 | 0.85 | CYP3A4 (0.51) | MMP13CYP3A4MMP7GPR119CTSS | |
| SCHEMBL3937231 | 0.84 | MMP13 (0.44) | MMP13CYP3A4MMP7KCNH2MMP14 | |
| SCHEMBL13923644 | 0.83 | MMP13 (0.68) | MMP13CYP3A4MMP7KCNH2MMP14 | |
| SCHEMBL3933431 | 0.83 | MMP13 (0.68) | MMP13CYP3A4MMP7KCNH2MMP14 | |
| SCHEMBL6644045 | 0.81 | CYP3A4 (0.43) | MMP13CYP3A4MMP7MMP14DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485644-B2 | N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| EP-1644340-B1 | N-[({'4-SUBSTITUTED PIPERAZINE-1-YL}SULFONYLMETHYL)ALKYL]-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| EP-1644340-A1 | N-{'4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL]ALKYL}-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005000822-A1 | N-{‘4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL!ALKYL}-N-HYDROXYFOMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | MMP26, MMP9, MMP3 | MMP13 8/4885CYP3A4 466/4885MMP7 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.